Clinical Trial Update: CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating CS1-CAR T cell therapy after chemotherapy in patients with relapsed or refractory CS1-positive multiple myeloma is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CS1-CAR T therapy (CS1-CAR T)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Status: RECRUITING